These findings highlight the potential of COX-2-predicted responses to immunotherapy in HCC patients with high SMIM25 expression, while also offering valuable insights into the development of novel immunotherapeutic strategies for HCC. The gene discussed is PTGS2; the disease is hepatocellular carcinoma.